Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Efficacy, Team × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 10998 Neoplasms 8807 Carcinoma, Non-Small-Cell Lung 5711 Prostatic Neoplasms 5278 Colorectal Neoplasms 4951 Lung Neoplasms 4210 Pancreatic Neoplasms 3003 Multiple Myeloma 3001 Neoplasm Metastasis 2954 Leukemia, Myeloid, Acute 2927 Carcinoma, Hepatocellular 2734 Ovarian Neoplasms 2657 Melanoma 2635 Stomach Neoplasms 2567 Lymphoma 2502 Head and Neck Neoplasms 2162 Recurrence 2132 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2069 Leukemia 1992 Brain Neoplasms 1971 Colonic Neoplasms 1939 Lymphoma, Non-Hodgkin 1894 Rectal Neoplasms 1846 Uterine Cervical Neoplasms 1806 Glioblastoma 1699 Leukemia, Lymphocytic, Chronic, B-Cell 1663 Carcinoma, Renal Cell 1597 Squamous Cell Carcinoma of Head and Neck 1550 Lymphoma, Follicular 1526 Esophageal Neoplasms 1516

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡